Abstracts tagged "nanomedicine and rheumatoid arthritis"

Abstract Number: 2344 • 2014 ACR/ARHP Annual Meeting
Amelioration of Collagen-Induced Arthritis By Water-Soluble Fullerene C60(OH)₃₆ Nanoparticles through the Inhibition of Angiogenesis
Chia-Tse Weng^1,2, Shih-Yao Chen³, Yu-Hung Chen⁴, Chao-Liang Wu³, Ming-Fei Liu^1,2, Ai-Li Shiau⁵ and Chrong-Reen Wang^1,2, ¹Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ⁵Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose Our previous study has shown that injection of 13-nm gold nanoparticles ameliorates collagen-induced arthritis (CIA) through the inhibition of angiogenesis by binding to VEGF.…
Abstract Number: 1634 • 2012 ACR/ARHP Annual Meeting
Delivering Mesenchymal Stem Cells to Arthritic Joints with Nano-Fiber Scaffold Resulted in Inhibition of Arthritis and Joint Damage in Arthritis Models
Xiangmei Zhang¹, Kunihiro Yamaoka¹, Koshiro Sonomoto¹, Masahiro Kondo¹, Shunsuke Fukuyo¹, Makoto Satake², Hiroaki Kaneko², Kazuhisa Nakano¹, Shingo Nakayamada³, Yosuke Okada¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The Third Laboratory, Integrative Technology Research Institute, Teijin Limited, Tokyo, Japan, ³First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Even though treatment of rheumatoid arthritis (RA) has emerged, aiming bone repair is still a challenge. Mesenchymal stem cells (MSCs) possess immunoregulatory function with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].